| 乐伐替尼治疗恶性肿瘤的研究进展 |
| |
| 引用本文： | 于悦,时静,刘玉国.乐伐替尼治疗恶性肿瘤的研究进展[J].中国医院药学杂志,2018,38(9):1005-1009. |
| |
| 作者姓名： | 于悦 时静 刘玉国 |
| |
| 作者单位： | 1. 济南大学山东省医学科学院医学与生命科学学院, 山东 济南 250200;
2. 山东大学附属山东省肿瘤医院药学部, 山东 济南 250117 |
| |
| 摘 要： | 乐伐替尼是一种口服的多靶点酪氨酸激酶受体抑制剂，用于放射性碘难治性分化型甲状腺癌的单药治疗以及与依维莫司联合治疗晚期肾细胞癌。近年越来越多的临床数据展示出了该药在未来抗肿瘤治疗中的巨大潜力。本文将对其作用机制、研究历程、临床试验以及最新研究进展进行综述，以求使读者能够更全面地了解和认识乐伐替尼并且为我国的临床实践提供建议。
|
| 关 键 词： | 乐伐替尼 酪氨酸激酶受体抑制剂 抗血管生成 分子靶向治疗 肿瘤 甲状腺癌 肾细胞癌 |
| 收稿时间： | 2017-09-14 |
Current status and development of lenvatinib in the treatment of malignant tumors |
| |
| YU Yue,SHI Jing,LIU Yu-guo.Current status and development of lenvatinib in the treatment of malignant tumors[J].Chinese Journal of Hospital Pharmacy,2018,38(9):1005-1009. |
| |
| Authors: | YU Yue SHI Jing LIU Yu-guo |
| |
| Institution: | 1. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Shandong Jinan 250200, China;
2. Department of Pharmacy, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Jinan 250117, China |
| |
| Abstract: | Lenvatinib is an oral multi-target tyrosine kinase receptor inhibitor for monotherapy against radioiodine refractory, differentiated thyroid cancer and for the treatment of advanced renal cell carcinoma with everolimus. In recent years, more and more clinical data show the great potential of the drug in future antitumor therapy. This paper will review its mechanism, course of study, clinical trials and the latest researches in order to enable readers to learn lenvatinib better and provide recommendations for our clinical practice. |
| |
| Keywords: | lenvatinib tyrosine kinase inhibitors receptor anti-angiogenesis molecular targeted therapy tumor thyroid cancer renal cell carcinoma |
|
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
| 点击此处可从《中国医院药学杂志》下载免费的PDF全文 |
